This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...
The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to sever ...
7h
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...
More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
The Decatur County Community Foundation has received a $5 million grant to create a Crisis Intervention Team in Decatur County. Jail Commander Mike Eggleston and Decatur County Community Foundation ...
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...
Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback